RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Zealand Pharma A/S Stock

Zealand Pharma A/S ROA 2024

Zealand Pharma A/S ROA

-0.36

Ticker

ZEAL.CO

ISIN

DK0060257814

WKN

A0YJW7

In 2024, Zealand Pharma A/S's return on assets (ROA) was -0.36, a -54.47% increase from the -0.78 ROA in the previous year.

Zealand Pharma A/S Aktienanalyse

What does Zealand Pharma A/S do?

Zealand Pharma A/S is a biopharmaceutical company specializing in the discovery and development of therapeutics, particularly in the field of diabetes, gastrointestinal, and metabolic diseases. The company aims to improve the quality of life for patients with chronic conditions. Zealand Pharma's business model is based on the discovery, development, and commercialization of novel peptide-based therapeutics, utilizing their own technology platform and partnering with pharmaceutical industry collaborators. Their portfolio includes innovative product candidates such as the diabetes treatment Adlyxin and Lixisenatide, both GLP-1 agonists developed in collaboration with Sanofi. They also have products for the treatment of gastrointestinal and heart diseases. Zealand Pharma has a wide pipeline of product candidates at various stages of development, including for the treatment of obesity, fatty liver diseases, and other metabolic conditions. The company works closely with partners such as Sanofi, Boehringer Ingelheim, and Roche. Zealand Pharma is listed on NASDAQ OMX Copenhagen and employs over 200 people in Denmark and the USA. Overall, Zealand Pharma is an innovative biopharmaceutical company with a diverse portfolio of product candidates, focused on collaboration to accelerate product development and improve the quality of life for patients with chronic conditions. Zealand Pharma A/S ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Zealand Pharma A/S's Return on Assets (ROA)

Zealand Pharma A/S's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Zealand Pharma A/S's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Zealand Pharma A/S's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Zealand Pharma A/S’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Zealand Pharma A/S stock

What is the Return on Assets (ROA) of Zealand Pharma A/S this year?

The Return on Assets (ROA) of Zealand Pharma A/S is -0.36 undefined this year.

What was the ROA of Zealand Pharma A/S compared to the previous year?

The ROA of Zealand Pharma A/S has increased by -54.47% compared to the previous year.

What consequences do high ROA have for investors of Zealand Pharma A/S?

A high ROA is advantageous for investors of Zealand Pharma A/S, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Zealand Pharma A/S?

A low ROA can be unfavorable for investors of Zealand Pharma A/S as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Zealand Pharma A/S affect the company?

An increase in ROA of Zealand Pharma A/S can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Zealand Pharma A/S impact the company?

A reduction in the ROA of Zealand Pharma A/S can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Zealand Pharma A/S?

Some factors that can influence the ROA of Zealand Pharma A/S include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Zealand Pharma A/S important for investors?

The ROA of Zealand Pharma A/S is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Zealand Pharma A/S take to improve ROA?

To improve ROA, Zealand Pharma A/S can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Zealand Pharma A/S pay?

Over the past 12 months, Zealand Pharma A/S paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Zealand Pharma A/S is expected to pay a dividend of 0 DKK.

What is the dividend yield of Zealand Pharma A/S?

The current dividend yield of Zealand Pharma A/S is .

When does Zealand Pharma A/S pay dividends?

Zealand Pharma A/S pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Zealand Pharma A/S?

Zealand Pharma A/S paid dividends every year for the past 0 years.

What is the dividend of Zealand Pharma A/S?

For the upcoming 12 months, dividends amounting to 0 DKK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Zealand Pharma A/S located?

Zealand Pharma A/S is assigned to the 'Health' sector.

Wann musste ich die Aktien von Zealand Pharma A/S kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Zealand Pharma A/S from 10/2/2024 amounting to 0 DKK, you needed to have the stock in your portfolio before the ex-date on 10/2/2024.

When did Zealand Pharma A/S pay the last dividend?

The last dividend was paid out on 10/2/2024.

What was the dividend of Zealand Pharma A/S in the year 2023?

In the year 2023, Zealand Pharma A/S distributed 0 DKK as dividends.

In which currency does Zealand Pharma A/S pay out the dividend?

The dividends of Zealand Pharma A/S are distributed in DKK.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Zealand Pharma A/S

Our stock analysis for Zealand Pharma A/S Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Zealand Pharma A/S Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.